Evotec Reports Nine-Month 2026 Results Surpassing Expectations

Evotec SE, a prominent biotechnology company based in Hamburg, Germany, has announced its preliminary financial results for the first nine months of 2026. The company revealed that its revenues for this period are approximately €465.0 million, while the adjusted Group EBITDA stood at around -€42.8 million. These figures exceed market expectations, primarily due to differences in the timing of consensus estimates.

Despite the preliminary nature of these results, Evotec remains confident in its financial stability and reaffirms its full-year 2026 guidance. The company anticipates Group revenues in the range of €570 to €610 million, with adjusted Group EBITDA projected between -€70 to -€105 million.